Cytokines and pancreatic cancer the effect of rIFN-γ, HuLelFN, rTNF-α, and LAK-cells on pancreatic and other gastrointestinal tumors in vitro
作者： Mohr H , Kühl Js , Klapdor R , Dietel M , Arps H
DOI: 10.1007/BF02931322
关键词: Endocrinology 、 Cytotoxicity 、 Lymphokine-activated killer cell 、 Cell 、 Pancreatic cancer 、 Doubling time 、 Cell culture 、 Biology 、 Immunotherapy 、 Cancer research 、 Internal medicine 、 CA19-9
摘要: A panel of 10 digestive tract carcinoma cell lines (6 pancreatic carcinomas) was assayed for their sensitivity to HuLelFN, human rIFN-7, rTNF-a and allogeneic LAK-cells in vitro. In addition, a combination rlFN-7 +rTNF-a tested on 3 lines. Whereas 6/7 were completely resistant rIFN-7 rTNF-α did inhibit growth some carcinomas tested. The individual heterogenous as is already known from cytostatics. Response rIFN-γ tended increase with increment doubling time. Only high concentrations (>1000 U/mL) displayed cytotoxicity sensitive tumors. antitumoral effect stimulated by rTNF-α. As revealed isobole analysis this interaction synergistic all comparison or the response slightly superior at effector target ratios, even though heterogenous.
springer.com
sci-hub.se 参考文章(20)
Elizabeth A. Grimm, Debra J. Wilson, The human lymphokine-activated killer cell system Cellular Immunology. ,vol. 94, pp. 568- 578 ,(1985) , 10.1016/0008-8749(85)90280-1
Morris C. Berenbaum, Criteria for Analyzing Interactions between Biologically Active Agents Advances in Cancer Research. ,vol. 35, pp. 269- 335 ,(1981) , 10.1016/S0065-230X(08)60912-4
Vito Ruggiero, Jan Tavernier, Walter Fiers, Corrado Baglioni, Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. Journal of Immunology. ,vol. 136, pp. 2445- 2450 ,(1986)
Steadman D. Harrison, Paul P. Trotta, Evaluation of the Antitumor Activity of Recombinant Human γ-Interferon Employing Human Melanoma Xenografts in Athymic Nude Mice Cancer Research. ,vol. 47, pp. 5347- 5353 ,(1987)
John Laszlo, David Goldstein, Interferon therapy in cancer: from imaginon to interferon. Cancer Research. ,vol. 46, pp. 4315- 4329 ,(1986)
Jordan U. Gutterman, Razelle Kurzrock, Moshe Talpaz, Stephen A. Sherwin, Michael G. Rosenblum, Adan Rios, Jorge R. Quesada, Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant γ-lnterferon in Cancer Patients Cancer Research. ,vol. 45, pp. 2866- 2872 ,(1985)
Zbigniew Darzynkiewicz, Elizabeth A. Carswell, Barbara Williamson, Lloyd J. Old, Cell Cycle-specific Effects of Tumor Necrosis Factor Cancer Research. ,vol. 44, pp. 83- 90 ,(1984)
Steven A. Rosenberg, Michael T. Lotze, Linda M. Muul, Susan Leitman, Alfred E. Chang, Stephen E. Ettinghausen, Yvedt L. Matory, John M. Skibber, Eitan Shiloni, John T. Vetto, Claudia A. Seipp, Colleen Simpson, Cheryl M. Reichert, Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer The New England Journal of Medicine. ,vol. 313, pp. 1485- 1492 ,(1985) , 10.1056/NEJM198512053132327
M. Dietel, H. Arps, R. Klapdor, S. M�ller-Hagen, M. Sieck, L. Hoffmann, Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients' sera Journal of Cancer Research and Clinical Oncology. ,vol. 111, pp. 257- 265 ,(1986) , 10.1007/BF00389242
Kiyotaka Okuno, Hiromi Takagi, Tetsuhiko Nakamura, Yohsuke Nakamura, Zenji Iwasa, Masayuki Yasutomi, Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer. ,vol. 58, pp. 1001- 1006 ,(1986) , 10.1002/1097-0142(19860901)58:5<1001::AID-CNCR2820580502>3.0.CO;2-K